Culture and multiomic analysis of lung cancer patient-derived pleural effusions revealed distinct druggable molecular types

Ha-Young Seo\textsuperscript{1,3,6}, Soon-Chan Kim\textsuperscript{1,2,3,4,6}, Woo-lee Roh\textsuperscript{1}, Young-Kyoung Shin\textsuperscript{1}, Soyeon Kim\textsuperscript{1}, Dong-Wan Kim\textsuperscript{3,5}, Tae Min Kim\textsuperscript{3,5} & Ja-Lok Ku\textsuperscript{1,2,3,4}\textsuperscript{*}

Malignant pleural effusion (MPE) is an independent determinant of poor prognostic factor of non-small cell lung cancer (NSCLC). The course of anchorage independent growth within the pleural cavity likely reforms the innate molecular characteristics of malignant cells, which largely accounts for resistance to chemotherapy and poor prognosis after the surgical resection. Nevertheless, the genetic and transcriptomic features with respect to various drug responses of MPE-complicated NSCLC remain poorly understood. To obtain a clearer overview of the MPE-complicated NSCLC, we established 28 MPE-derived lung cancer cell lines which were subjected to genomic, transcriptomic and pharmacological analysis. Our results demonstrated MPE-derived NSCLC cell lines recapitulated representative driver mutations generally found in the primary NSCLC. It also exhibited the presence of distinct translational subtypes in accordance with the mutational profiles. The drug responses of several targeted chemotherapies accords with both genomic and transcriptomic characteristics of MPE-derived NSCLC cell lines. Our data also suggest that the impending drawback of mutation-based clinical diagnosis in evaluating MPE-complicated NSCLC patient responses. As a potential solution, our work showed the importance of comprehending transcriptomic characteristics in order to defy potential drug resistance caused by MPE.

Lung cancer is one of the most prevalent cause of cancer-related death worldwide, with an estimated one million deaths annually. Within Korean population, it is the most lethal disease and the third common types of cancer\textsuperscript{1,2}. It is also the most prevailing cause of malignant pleural effusion (MPE), accounting for approximately 30% of such effusions\textsuperscript{3}. Although recent advances in prevention and early detection have contributed to the general increase in the survival rate, the occurrence of MPE in the context of lung cancer designates terminal stage and an independent prognostic parameter of the poorer survival rate\textsuperscript{4}. Lung cancer patients with MPE mostly exhibit insensitivities to certain chemotherapies mainly due to high tumor burden\textsuperscript{5,6}. Besides, the course of acquiring anoikis resistance alters multiple tumorigenic pathways, which eventually brings about insensitivity to certain chemotherapies\textsuperscript{7}. Nevertheless, the genetic and transcriptomic features with respect to various drug responses of MPE-complicated NSCLC have not been thoroughly studied yet, which makes the implication of drug insensitivities of MPE-derived tumor cell still hypothetical.

Moreover, several studies have indicated that acquired resistance to second line chemotherapy such as crizotinib is associated with aggressive disease progressions\textsuperscript{8}. Nevertheless, the widely accepted oncogenic association of secondary or tertiary alternations by the second line chemotherapy has been focused on the primary NSCLC, and oncogenic impact of chemotherapy-derived molecular changes in MPE remains unclear.

To obtain a clearer overview of the MPE-complicated NSCLC in accordance with heterogeneous drug responses, we established 28 lung cancer cell lines derived directly from the MPE, and two crizotinib-resistant sublines which were then subjected to genomic, transcriptomic and pharmacological analysis. Our results not only showed that MPE-derived NSCLC cell lines recapitulated representative genetic aberrations of the primary

\textsuperscript{1}Korean Cell Line Bank, Laboratory of Cell Biology, Cancer Research Institute, Seoul National University College of Medicine, 103, Daehak-ro, Jongno-gu, Seoul 03080, Korea. \textsuperscript{2}Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Korea. \textsuperscript{3}Cancer Research Institute, Seoul National University, Seoul 03080, Korea. \textsuperscript{4}Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul 03080, South Korea. \textsuperscript{5}Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Korea. \textsuperscript{*}These authors contributed equally: Ha-Young Seo and Soon-Chan Kim. \textsuperscript{email: kujalok@snu.ac.kr}
NSCLC including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) fusion with other domains, but also demonstrated the presence of distinct translational subtypes in accordance with the mutational profiles, which was consistently reflected to the drug responses of certain targeted chemotherapies. Our data also suggest that the inherent downside of mutation-based clinical diagnosis in assessing MPE-complicated NSCLS patient responses. As a potential solution, our data showed the importance of comprehending transcriptomic characteristics in order to defy potential drug resistance caused by MPE.

**Results**

**MPE-derived human lung adenocarcinoma cell lines displayed various growth patterns.** The morphologies of the established cell lines were mainly categorized into four subtypes: polygonal, oval, fibroblast-like, and round (Fig. 1, Table 1). The doubling time of each cell lines varied with a range of 25 to 102 h (Table 1). We made sure the confluency of each cell lines are 50–80% so that the morphologies of cell lines were not affected by different level of contact inhibition. Although original tumor cells were derived from the MPE, which was expected to have resistance to anoisiks, only two cell lines (SNU-2708.1 and SNU-3023) formed floating aggregates exhibiting round morphology. This suggests that all but two floating cell lines retained the nature of adherent growth patterns in the pleural cavity. There was also intra-morphological heterogeneity within a same cell population. For instance, the culture of SNU-2681 exhibited both round and polygonal tumor cells, which indicates the heterogeneous lung adenocarcinoma populations were retained in the in vitro culture.

DNA fingerprinting analysis identified a heterogeneous distribution of 15 tetranucleotide repeat loci and an Amelogenin gender determining marker in each cell line, and confirmed 28 unique cell lines without cross-contamination (Supplementary Fig. 1). The precise exclusion of the germinant mutations was not feasible since the DNA from matched blood or normal tissue was unavailable when WES of established cell lines was performed. Alternatively, we have referred to the Clinvvar database (https://www.ncbi.nlm.nih.gov/clinvvar) in order to avoid misestimating the mutation frequency due to inflated germinant/benign mutations. The pathogenicity of the representative driver mutations was manually inspected, and all marked mutations for calculating the frequency of mutated tumor genes in Fig. 2A were previously reported as "Pathogenic," "likely Pathogenic" or "Drug Response" in the Clinvvar database.

**MPE-derived lung cancer cell lines retain the representative genetic mutations of human lung adenocarcinoma.** Several studies have shown that MPE-derived tumor cell lines maintain the mutational profiles of the lung adenocarcinoma$^{8,9}$. We performed whole exome sequencing (WES) and targeted sequencing (CCP) on the 28 MPE-derived cell lines. The overall mutational spectrum of the MPE-derived NSCLC cell lines such as mutant-allele tumor heterogeneity (MATH) analysis and relative contribution of mutational signatures was analyzed using WES data. The targeted sequencing as well as direct Sanger sequencing re-confirmed the presence of key driver mutations minimizing the possible false-positive sequencing errors (Supplementary Fig. 2, Supplementary Table 2). The precise exclusion of the germinant mutations was not feasible since the DNA from matched blood or normal tissue was unavailable when WES of established cell lines was performed. Alternatively, we have referred to the Clinvvar database in order to avoid misestimating the mutation frequency due to inflated germinant/benign mutations. The pathogenicity of the representative driver mutations was manually inspected, and all marked mutations for calculating the frequency of mutated tumor genes in Fig. 2A were previously reported as "Pathogenic," "Likely Pathogenic" or "Drug Response" in the Clinvvar database.

To establish a more comprehensive mutational profile, the aberrations in key driver genes were compared to a larger lung cancer cell line cohort from the cancer cell line encyclopedia project (CCLE)$^{10}$ which was composed of a total of 63 lung cancer cell lines (Fig. 2A). As a first validation, our cohort had a significantly higher rate of EGFR mutations (36%) compared to CCLE cohort (14%). It has been reported that the EGFR mutation frequency in lung adenocarcinoma is approximately 10% as much larger cohort (TCGA)$^{11}$ indicated (Supplementary Fig. 3). Pervasive EGFR mutation in our cohort was accordant with the previous MPE of lung adenocarcinoma study$^{12}$. In contrast, KRAS mutation was detected at a low rate in our cohort (7%) compared to CCLE (35%) and TCGA (30%) cohorts, which was unexpected since mutant KRAS is reported to promote malignant pleural effusion formation$^{9}$.

Previous study indicated that EGFR is more frequently aberrated than KRAS in Korean NSCLC population$^{13}$, which suggest that the geographic factor partially shaped the mutational landscape of our cohort. Nine patients harbored driver fusion genes including EML4-ALK, KIF5B-RET and CD74-ROS1 in our cohort (Supplementary Fig. 4). Few groups reported that lung cancer patients with fusion genes, especially EML4-ALK were younger than those without$^{14,15}$, which was in parallel with our data. The presence of fusion genes was mutually exclusive with EGFR and KRAS mutation in parallel with prior study$^{14,15}$.

We also calculated the heterogeneity scores by using a previously reported method, mutant-allele tumor heterogeneity (MATH)$^{16}$. This analysis allowed to estimate the dispersion of mutant allele frequencies (MAFs) within a cell population, which reflected the intra-tumor genetic heterogeneity. The cell lines with mutant EGFR had higher MATH score than two other groups, suggesting that higher level of genetic heterogeneity is causative factor for EGFR mutation (Fig. 2B). Then, we evaluated the relative contribution of single nucleotide variations (SNVs) to the mutational signature of each cell line using web-based algorithm, MUSICA. The most predominant point mutation type in the cell lines was the C-to-T transitions (Fig. 2C, Supplementary Table 3). Except for SNU-3023 that exhibited distinct configurations of the relative contribution of SNVs, all cell lines had analogous patterns. We then compared the most various mutational contribution among the three groups. A[T > C]C was the most different SNV signature followed by G[C > T][T] (Fig. 2D).

Overall, comprehensive mutational analysis indicated that there is a distinct separation of genomic drivers in our cohort: EGFR aberration, fusion genes, and others. We have applied these groups for further analysis of transcriptome and drug screening.
Transcriptomic analysis of MPE-derived lung cancer cell lines reveal a separation of EGFR and fusion types. We then verified that the pattern of mRNA expression reflects the distinctive genomic aberrations. The principle component analysis (PCA) of the mRNA expression indicated that MPE-derived cell lines were likely grouped in accordance with their genetic factors (Fig. 3A). Cell lines with EGFR mutation were specifically clustered with less degree of dispersion on the PCA plot compared to the fusion group, which suggests that EGFR-mutated NSCLCs in MPE display characteristic transcription patterns. Hierarchical clustering
| Cell Line | Culture site | Sex | Age | Pathology | Growth pattern | Doubling time(hr) | Cell morphology | Driver Event(s) |
|-----------|--------------|-----|-----|-----------|----------------|------------------|----------------|----------------|
| SNU-2535  | Pleural effusion | F   | 56  | ADC       | Adherent       | 61               | Polygonal       | EML4(exon13)-ALK(exon20) fusion, FGFR4 (G388R) |
| SNU-2550  | Pleural effusion | F   | 35  | ADC       | Adherent       | 32               | Oval            | EML4(exon6)-ALK(exon20) fusion |
| SNU-2553  | Pleural effusion | M   | 40  | ADC       | Adherent       | 61               | Fibroblast-like | EML4(exon20)-ALK(exon20) fusion |
| SNU-2556  | Pleural effusion | F   | 72  | ADC       | Adherent       | 35               | Oval            | EGFRI (E746_A750del), FGFR4 (G388R), TP53 (G154V) |
| SNU-2563  | Pleural effusion | M   | 49  | ADC       | Adherent       | 47               | Polygonal       | EML4(exon18)-ALK(exon20) fusion, TP53 (R208K) |
| SNU-2588  | Pleural effusion | M   | 75  | ADC       | Adherent       | 31               | Oval            | KRAS (G12V) |
| SNU-2589  | Pleural effusion | F   | 43  | ADC       | Adherent       | 39               | Polygonal       | FGFR4 (G388R), TP53 (P72R, G266R) |
| SNU-2596  | Pleural effusion | M   | 49  | ADC       | Adherent       | 47               | Oval            | KRAS (G12V), TP53 (R273C) |
| SNU-2612A | Pleural effusion | M   | 33  | ADC       | Adherent       | 28               | Oval            | CD74(exon6)-ROS1(exon34) fusion, FGFR4 (G388R), TP53 (R208K) |
| SNU-2627  | Pleural effusion | F   | 46  | NOS       | Adherent       | 30               | Oval            | FGFR4 (G388R) |
| SNU-2639  | Pleural effusion | F   | 52  | ADC       | Adherent       | 44               | Oval            | EGFRI (E746_A750del), FGFR4 (G388R), TP53 (G154V) |
| SNU-2641  | Pleural effusion | M   | 64  | NOS       | Adherent       | 21               | Oval            | EGFRI (E746_A750del), FGFR4 (G388R), TP53 (G154V) |
| SNU-2643  | Pleural effusion | F   | 57  | NOS       | Adherent       | 27               | Oval            | EGFRI (E746_A750del), FGFR4 (G388R), TP53 (G154V) |
| SNU-2668  | Pleural effusion | M   | 63  | ADC       | Adherent       | 34               | Polygonal       | ERBB2 (I655V), KRAS (G12C), TP53 (R273C) |
| SNU-2669  | Pleural effusion | F   | 74  | ADC       | Adherent       | 25               | Fibroblast-like/Oval | FGFR4 (G388R), TP53 (I195T) |
| SNU-2676  | Pleural effusion | M   | 60  | ADC       | Adherent       | 34               | Polygonal       | FGFR4 (G388R), TP53 (I195T) |
| SNU-2708.1| Pleural effusion | M   | 56  | ADC       | Floating       | -                | Round           | EGFRI exon19 deletion (L747_T751del), TP53 (G245V) |
| SNU-2727  | Pleural effusion | F   | 39  | ADC       | Adherent       | 102              | Polygonal       | EGFRI (L858R), ERBB2 (I655V), FGFR4 (G388R), TP53 (S183*) |
| SNU-2741  | Pleural effusion | M   | 57  | ADC       | Adherent       | 55               | Polygonal       | FGFR4 (G388R), EGFRI (L747_P753delinsS), TP53 (P72R, V143M) |
| SNU-2749  | Pleural effusion | M   | 67  | ADC       | Adherent       | 31               | Polygonal       | BRAF (V600E), ERBB2 (I655V), FGFR4 (G388R), TP53 (Q331*), FGFR4 (G388R) |
| SNU-2778  | Pleural effusion | M   | 54  | ADC       | Adherent       | 35               | Polygonal       | KIF5B(exon15)-RET(exon12) fusion, FGFR4 (G388R) |
| SNU-2832  | Pleural effusion | F   | 58  | ADC       | Adherent       | 25               | Fibroblast-like | CD74(exon6)-ROS1(exon34) fusion, ERBB2 (I655V) |
| SNU-2867  | Pleural effusion | M   | 57  | ADC       | Adherent       | 87               | Fibroblast-like/Polygonal | EGFRI (E746fs, L747fs), TP53 (H179R) |
| SNU-2887  | Pleural effusion | F   | 56  | ADC       | Adherent       | 102              | Polygonal       | EGFRI (E746_A750del), FGFR4 (G388R), TP53 (I195T) |
| SNU-2964  | Pleural effusion | M   | 64  | NOS       | Adherent       | 34               | Oval            | EGFR (L858R), ERBB2 (I655V), FGFR4 (G388R), TP53 (I195T) |
| SNU-3023  | Pleural effusion | F   | 70  | ADC       | Floating       | 29               | Round           | EGFRI (L858R), FGFR4 (G388R) |

Table 1. Clinicopathological features of 28 human lung cancer cell lines. ADC indicates adenocarcinoma, NOS indicates not otherwise specified.
aling pathway are summarized in Supplementary Table 4. GSEA analysis designates that the transcriptomic aberrations in the fusion gene group exhibited more specific patterns in tumor-related pathways than the EGFR group.

Induced resistance to crizotinib causes nuclear localization of β-catenin in MPE-derived NSCLC through increased DKK1 expression. An ALK inhibitor is the standard treatment for advanced NSCLC patients harboring the anaplastic lymphoma kinase (ALK) fusion gene. However, secondary ALK mutations or alternative pathway changes cause a fraction of the tumors to be resistant to ALK inhibitors. We further validated that the acquired resistance to crizotinib, the first generation of the ALK inhibitor, alters the transcriptional patterns of MPE-derived NSCLC cell lines harboring EML4-ALK fusion gene. We established two crizotinib-resistant sublines (SNU-2550CR and SNU-2563CR) by long-term exposure to increasing concentrations of crizotinib, and performed RNA-seq. Both sublines exhibited distinct insensitivities to crizotinib, and a list of differentially expressed genes and their log fold changes together with signaling pathways topology were identified in order to detect the pathways most relevant to the crizotinib resistance. SPIA two-way analysis of RNA-seq revealed multiple signaling aberrations including p53 signaling and focal adhesion (Fig. 4A,B). Specifically, the mRNA level of DKK1 which has been reported to promote the migration and invasion of NSCLC by inhibiting the phosphorylation of β-catenin, was significantly upregulated in both crizotinib resistant cell lines. The elevated expression of DKK1 was confirmed in mRNA (Fig. 4C) and protein (Fig. 4D) level. We further investigated the potential role of increased DKK1 expression in the context of β-catenin signaling. Immunocytochemistry indicated that the nuclear localization of β-catenin was significantly increased in both crizotinib-resistant cell lines (Fig. 4E,F).

MPE-derived NSCLC cell lines reveal heterogeneous drug responses caused by molecular diversity. We assembled an 18-compound library for drug screening. In total, 30 cell lines including two crizotinib resistant sublines from 28 patients were successfully screened in experimental triplicate, generating > 500 measurements of cell line-drug interactions.

As a first validation, k-means clustering of AUC values indicated that both cell lines and drugs were likely grouped with their molecular subtypes. For instance, MPE-derived NSCLC cell lines with EGFR mutations such as

Figure 2. The characteristic genetic mutations of MPE-derived lung cancer cell lines. (A) See also Table 1. Comparison between the mutational landscape of MPE-derived cell lines (n = 28) and CCLE-LUAD cell lines (n = 63). MPE-derived cell lines harbored higher rates of the EGFR mutation as well as the fusion events. Each type of mutations is marked with representative colors on the waterfall plot. The total mutational loads are indicated on the top (per each cell lines) and right side (per each cohorts) of the plot. The percentage of mutational occurrence within the cohort is specified on the left side of the plot. (B) See also Supplementary Table 3. The MATH score demonstrated EGFR-mutant group had higher genetic heterogeneity score. Interquartile ranges with the median value are indicated on the box plot. Each group is marked with representative colors. (C) The relative contribution of SNVs for each cell lines. Most cell lines exhibited similar patterns except for the SNU-3023. Six different substitution types are designated with representative colors. (D) Top 10 different SNV contribution between the mutational subtypes. Each groups are marked with representative colors.
as SNU-2556, SNU-2643, SNU-2708.1, SNU-2741, SNU-2867, SNU-2887, SNU-2964 and SNU-3023 as well as EGFR inhibitors including gefitinib, erlotinib and dacomitinib were tightly clustered together. Moreover, MPE-derived NSCLC cell lines with EML4-ALK fusion and its targeted drugs including crizotinib, alectinib, and ceritinib were grouped as well (Fig. 5A and Supplementary Table 5).

Among the MPE-derived NSCLC cell lines harboring fusion genes, two cell lines with the CD74-ROS fusion gene were selectively sensitive to MK-5108, an Aurora A inhibitor (marked with triangle Fig. 5A). Two crizotinib-resistant sublines displayed insensitivities to other next generation ALK inhibitors including alectinib and ceritinib as well. In accordant with the previous study21, ceritinib displayed better responses compared to two other ALK-inhibiting reagents. ICG-001, a β-catenin/CBP interaction inhibitor specifically exhibited good response on both crizotinib-resistant sublines (marked with rectangle Fig.s), which recapitulated the role of the increased nuclear localization of β-catenin caused by the elevated DKK1 on the crizotinib resistance.

We further integrated the genetic factors of the MPE-derived NSCLC cell lines with 18 drugs using Wilcox ranked sum test (Fig. 5B). Gene-drug interaction analysis not only reconfirmed that EGFR targeted therapy effectively worked on the EGFR-mutated cell lines, but also revealed that cell lines harboring the EML4-ALK fusion displayed significant insensitivities to EGFR targeted therapy. As indicated earlier, cell lines with CD74-ROS fusion were specifically sensitive to MK-5108 as well as cyclopamine.

Although gene-drug interaction analysis demonstrated the heterogeneous drug responses in accordance with the presence of the molecular target, more comprehensive interpretation was achieved by transcriptomic clustering. We performed multivariate analysis of variance (MANOVA) to find which drugs accorded with the three different transcriptional subtypes. MANOVA indicated that EGFR TKIs were significantly associated with the mRNA expression patterns (Supplementary Table 6). For instance, SNU-2585 and SNU-2588 cell lines were free of EGFR mutations, yet still positioned adjacent to cell lines with EGFR mutations on the transcriptomic analysis. This mRNA expression pattern is reflected by the notably good responses of these cell lines to EGFR TKIs, which suggests that the shape of transcriptomic landscape can be a determinant factor for EGFR-targeting therapy (Fig. 5C). In order to further associate the transcriptomic expression patterns to the drug responses, we then calculated the Pearson correlation coefficient with p values between the transcriptional heterogeneity score (DEPTH) and AUCs of each drug. The AUC value of cyclopamine was in direct proportion to the DEPTH score (Fig. 5D). Then, we integrated the genetic factors with the response to cyclopamine in order to further explain outliers. The mutational status of ERBB2 was highly associated with the correlation coefficient of DEPTH score.

Figure 3. EGFR and fusion subtypes are separated in transcriptomic patterns. (A) Principle component analysis indicated that MPE-derived cell lines with fusion events exhibited higher transcriptional heterogeneity than EGFR-mutant types. The principle component 1 and 2 accounted for 13.94% and 11.23% of the total loading components respectively. Each group is marked with representative colors. (B) Hierarchal clustering analysis demonstrated there are characteristic expressional patterns between EGFR-mutant and fusion gene groups. Cell lines with mutated genes other than the EGFR and fusion gene are not clustered. Each groups are marked with representative colors. (C) See also Supplementary Table 4. GSEA analysis revealed that spermatogenesis pathway is upregulated in EGFR-mutant groups compared to the other cell lines. (D) See also Supplementary Table 4. Hypoxia pathway is distinctively expressed in fusion gene group. The statistical settings for GSEA analysis is as follows (Number of permutations = 1000, Permutation type = phenotype, Chip platform = MSigDB.v.7.4.chip, Enrichment statistic = weighted, Max size: exclude larger sets = 500, Min size: exclude smaller sets = 15).
with the AUC of cyclopamine (Fig. 5E). Most of the cell lines with mutated ERBB2 located outside of the confidence interval and had reverse correlation of DEPTH score with the AUC of cyclopamine.

Discussion
Nearly 20% of lung cancer patients develop malignant pleural effusions (MPEs)\(^22,23\). MPE is an indicator of the poorer survival rate in lung cancer patients (about 7.5 months) compared to those without effusions (about 12–18 months)\(^23\). In the tumor-node-metastasis (TNM) staging classification of lung cancer, patients with MPE are categorized as category M1a (stage IV) as it is a sign of metastatic dissemination\(^24\). Although few studies have focused on malignant tumor cells from pleural fluids, only genomic analysis including mutational aspects and copy number variations was conducted\(^25–27\). Giuseppe Roscilli et al. integrated the mutational characteristics of human lung adenocarcinoma cells derived from MPEs to the patients chemosensitivity\(^6\), yet the number of included drugs and patients were not enough to draw solid conclusion.

In this study, we present 28 MPE-derived lung cancer cell lines and two crizotinib resistant sublines that were comprehensively characterized in accordance with multiple drug responses. These in vitro models retained the representative lung cancer mutations in parallel with mutational profiling of other external datasets consisting of lung cancer cell lines (CCLE) as well as tumor samples (TCGA). Our data revealed that MPE-derived lung cancer cell lines involves higher rates of \(EGFR\) mutations and fusion events compared to the lung adenocarcinoma-originated cell lines. Supporting the notion of distinguished \(EGFR\) and fusion aberrations, our transcriptomic analysis demonstrated that MPE-derived cell lines were subtyped in parallel with the genetic aberrations. The transcriptomic subtyping of \(EGFR\)-mutant NSCLC has been performed in other studies as well\(^28,29\). Our study has demonstrated that MPE-derived NSCLC cell lines also retain the transcriptional characteristics of \(EGFR\)-mutant NSCLC, which were distinctive to NSCLC cell lines with other driver mutations such as \(KRAS\) or fusion genes.

We suggested that the nuclear localization of \(\beta\)-catenin in MPE-derived \(\beta\)-catenin through increased DKK1 expression potentially caused crizotinib resistance. The acquire crizotinib resistance has been also associated with both MET amplification and exon 14 skipping mutation in lung cancer\(^30\). We further inspected if MET aberrations occurred in our two crizotinib sublines as well. We confirmed that MET was clearly amplified in SNU-2550CR cell line compared to its parental SNU-2550 cell line regardless of crizotinib treatment, yet no MET amplification was found in SNU-2563 and SNU-2563CR cell lines. This suggested that MET amplification indeed accounted for acquired crizotinib resistance in SNU-2550 set, and the SNU-2563CR cell lines had different resistance mechanism such as nuclear localization of \(\beta\)-catenin. No MET mutation was found in both resistant sublines.

Our work also enabled the integration of highly prevalent genetic and transcriptional characteristics of MPE-derived lung cancer cell lines to various drug responses. We re-confirmed that targeted therapies, especially \(EGFR\) TKIs showed high sensitivities in accordance with the presence of key mutations using Wilcoxon ranked sum test (Fig. 5B) and MANOVA (Supplementary Table 6) as reported by several previous studies. Remarkably,
Figure 5. MPE-derived NSCLC Cell Lines Reveal Heterogeneous Drug Responses Caused by Molecular Diversity. (A) See also Supplementary Table 5. Heatmap of MPE-derived NSCLC cell lines exhibited heterogeneous distribution of 18 compounds according to their molecular characteristics. The names of compounds are provided on the right. The cell lines and drugs were k-means clustered based on the AUC values across the drug panel. The mutational status of EGF, ERBB2, TP53 and three fusion genes, EMLA-ALK, CD74-ROS, KIF5B-RET are specified above the heatmap. (B) Volcano plot of gene-drug interaction analysis using Wilcoxon test. Each dot indicated a pair of gene and drug. The size of the circle is proportional to the sample size. When the mutational event was correlated to increased AUC values, the mutation was designated as resistant and colored in red. If the mutation was associated with decreased AUC values, it was assigned as sensitive and colored in blue. The absolute log fold change of AUC value > 0.2 and p < 0.05 were considered as significant. (C) See also Supplementary Table 6. The box plot of four EGFR-targeting drugs. Inter quartile ranges with the median value are indicated on the box plot. Each group is indicated by representative colors. The names of two outliers (SNU-2585 and SNU-2588) are specified. (D) The Pearson correlation coefficient (R) with p values between the transcriptomic ITH score and AUC of cyclopamine are indicated on the top of the correlation graph. Each dot represents each cell lines. The confidence interval is designated by a shading along with the correlation graph. (E) The direct correlation between AUC of cyclopamine and DEPTH is inversely correlated by the mutational status of ERBB2. Cell lines with mutant ERBB2 are separated from the correlation graph and colored in red. The Pearson correlation coefficient (R) with p values is re-calculated according to the mutational status of ERBB2.

we identified two EGFR-wild type cell lines (SNU-2585 and SNU-2588) were exceedingly sensitive to EGFR-targeting drugs. Those two cell lines showed even better response to Dacomitinib and Afatinib than EGFR-mutant cell lines (Fig. 3C). Hierarchical clustering analysis using transcriptomic landscape demonstrated that both cell lines were tightly clustered with the EGFR-mutant group (Fig. 3B), which enabled us to conclude that the translational profile can also be a determinant factor for accessing the drug response of targeted therapy. In this perspective, we suggest the downside of using mutation and transcriptomic data separately in clinical diagnosis when predicting MPE-complicated NSCLC patient responses. In analogous with this result, the correlation between the response of MPE-derived NSCLC cell lines to Cyclopamine and transcriptional heterogeneity score (DEPTH) depended on the mutational status of ERBB2 (Fig. 5E).

In conclusion, our work emphasized the significance of integrating the mutational status with transcriptomic subtypes using statistical models such as Pearson correlation coefficient and MANOVA in order for the accurate assessment of drug responses in lung cancer patients with MPE.

Methods

Establishment and maintenance of human NSCLC cell lines. The research protocol was reviewed and approved by the institutional review board of the Seoul National University Hospital (IRB No. 1102-098-357). The study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients enrolled in this study.

Cell lines were established from malignant pleural effusion (MPE) derived from pathologically proven non-small cell lung cancer (NSCLC). A total of 28 MPE specimens of human NSCLC from 28 different patients who underwent a pleural intervention for the palliation of dyspnea were obtained from Seoul National University Hospital (Seoul, Korea). MPE samples were directly transferred from the operating room to the laboratory for cell culture. Tumor cells were spun down by centrifugation the MPE sample at 300 rpm for 5 min, and re-suspended with Opti-MEM I (GIBCO, CA, USA) supplemented with 5% fetal bovine serum (GE Healthcare Life Sciences, Buckinghamshire, UK) and 1% Penicillin/Streptomycin. Gathered cells were then seeded into T-25cm² flasks with Opti-MEM I (GIBCO, CA, USA) supplemented with 5% fetal bovine serum (GE Healthcare Life Sciences, Buckinghamshire, UK) and 1% Penicillin/Streptomycin. Cultures were maintained in humidified incubators at 37 °C in an atmosphere of 5% CO₂ and 95% air.

The initial passage was assigned when substantial tumor cell growth was detected, and successive passages were given at sub-confluence after trypsinization. When one culture population contains both floating and adherent cells, floating cells were gathered by centrifuging the medium and dispersed by pipetting. All cell lines introduced in this study will be deposited in the Korean Cell Line Bank (http://cellbank.snu.ac.kr) at the initial passage in order to be distributed to researchers worldwide.

Growth properties and morphology in vitro. To calculate doubling time, the density of 5 × 10⁴/ml viable cells were seeded into 96 well cell culture plate with a volume of 200 μl, and cell viability was calculated daily for 7–14 days. Once 10 μl of EZ-Cytox solution (Daeil Lab, Seoul, Korea) was added, the plate was incubated at 37 °C for 2 h, and the optical density of each well was calculated by Multiskan™ GO Microplate Spectrophotometer (Thermo Fisher Scientific, MA, USA) at 450 nm wavelength. Acquired growth rate values were calibrated with GraphPad Prism 5 (GraphPad Software, CA, USA). The morphology of each cell lines was obtained using phase-contrast microscopy. Mycoplasma contamination was checked by the 16S-rRNA-gene-based polymerase chain reaction (PCR) amplification method using e-Myco Mycoplasma PCR Detection Kit (Intron Biotechnology, Gyeonggi, Korea).

Genomic DNA extraction and DNA fingerprinting analysis. Genomic DNA extraction was performed using QIAamp DNA Mini kit (Qiagen). Genomic DNA extracted from each lung cancer cell line was...
amplified using an AmpFISTR identifier Polymerase Chain Reaction (PCR) Amplification Kit (Applied Biosystems, CA, USA). A single cycle of PCR amplified 15 short tandem repeat markers (CSF1PO, D2S1338, D3S1358, D5S818, D7S820, D8S1179, D13S317, D16S539, D18S51, D19S433, D21S11, FGA, TH01, TPOX and vWA) and an Amelogenin gender-determining marker containing highly polymorphic microsatellite markers. Amplified PCR products were analyzed by an ABI 3500XL Genetic analyzer (Applied Biosystems).

**RNA extraction and reverse transcriptase (RT)-PCR.** To obtain RNA, TRIzol (ambion by Invitrogen, CA, USA) was added to cell pellet acquired from cultured lung cancer cell line. After cell lysis was happened, chloroform was added. Then, the sample was vortexed and 4 °C, 12,000 g centrifugation. Each tube containing the sample was divided into aqueous phase, interphase, and organic phase. In those aqueous phase was transferred into new tube. Isopropanol alcohol was mixed with an equal part of the aqueous phase. Mixed sample was centrifuged at 4 °C, 12,000 g after incubated at −20 °C. RNA was acquired from pellet. The pellet was precipitated by ethanol. RNA was melted in 4th Distilled water containing RNase inhibitor (DEPC). Complementary DNA (cDNA) was synthesized from extracted RNA by reverse transcription kit (Qiagen, MD, USA). Generally measured concentration of RNA was adjusted to 1ug diluted with gDNA wipeout buffer. Extracted RNA concentration was measured nano-spectrometer (Thermo Fisher Scientific, MA, USA). Each 1ug RNA was mixed with RT buffer, RT primer mix, and RTase. Those compounds were heated 42 °C for 30–45 min purpose on annealing, extension. Heated compound was additionally heated 95 °C for 3 min to denature synthetic cDNA. The list of primers we have used are as follows.

| Name | Forward primer sequence | Reverse primer sequence | Annealing temperature (°C) |
|------|-------------------------|-------------------------|----------------------------|
| KIF5B exon 15—RET exon 12 fusion | TAAAGGAAATGACCACCAACCACAG | GAAGTTGGAGAAATGGCATCAAGG | 60 |
| KIF5B exon 16—RET exon 12 fusion | GTGAAACGCTGAAACCTCTCTGAAG | CAGTTAG | 60 |
| EML4 exon 6—ALK exon 20 fusion | GCCATGGAGTCATCATCAACAA | CCAAG | 60 |
| EML4 exon 13—ALK exon 20 fusion | GTGCACTGGTTATAGCTCGTGGGG | TCTTGCCAGCAAAGCGATATTGAGTGGCAAGT | 60 |
| EML4 exon 18—ALK exon 20 fusion | GTCTGGTGTCGTCAGTGAAGA | AACACGAGATCT | 60 |
| EML4 exon 20—ALK exon 20 fusion | GGCGTCTCGACGCTCAACACAC | CAAAGG | 60 |
| CD74 exon 5—ROS1 exon 34 fusion | CCTGGAGACACCTTTAAGAAGACCA | TGAACCTGTCTTCTGTGATATCCCA | 57 |
| EGFR exon 19 deletion | TGTGGAGCCCTCTCATACCC | AAGCGGACTGAGGACCATAT | 60 |
| EGFR c.2602 T > G (p.L858R) | ATGTGGCAGGGAACCAAGAC | CATCCGAGCTTGAGCATGA | 60 |
| KRAS exon1 codon12-13 | TGACTGAATATAAACCTTTGAGTAG | TGTCCACAATAATGATCTGAAA | 59 |
| BRAF c.1799 T > A (p.V600E) | TGCTGACTAGAGAAGAGAGAT | GGCGAAAATTTATACAGTGAG | 61 |
| ERBB2 c.1963A > G (p.I655V) | GGACACGCTCTGTGGGAC | TGCAGCAGCGGACATCCA | 60 |
| FGF11 c.1162G > A (p.G388R) | CGAGGCCCCGATATAGCAGGAC | CAAAAGGCGCTGCAGCTACT | 63 |
| TP53 exon4 | TCTCGCTGGCTTCAAAAGAT | AACCTTCGATGCTGCTGTGTTG | 60 |
| TP53 exon7 | CTGGGCTGGTGGCTAAGGAC | AGGAGCTGTGGTGGTGGGG | 61 |
| TP53 exon8 | CCTCTCTTCTAGCTGAGGCC | CAAATGGCCCCATGAGGTTG | 60 |
| ALK kinase domain | GGAGGGTGATGAAAGCCGAGG | TCAGGAGGAGACTGAGGTGGG | 61 |
| ALK kinase domain (S1206Y, G1269A mutation target) | ACCAAAGATGTCCTGGTGGGG | CACCTAACTGGCAGAGTGGGG | 61 |
| ROS1 kinase domain | CTGGGCTAGCATCGTCTGGAAT | GCATTCCCTGTCAGATGGG | 63 |

**Complementary DNA synthesis.** For cDNA synthesis, QuantiTect Reverse Transcription Kit (Qiagen) was used. One microgram of total RNA, 2 μL of gDNA Wipeout Buffer, and RNase free water up to 14 μL were mixed together and incubated at 42 °C for 2 min. The mixture was mixed with Quantiscript RT Buffer, RT Primer Mix, and Quantscript Reverse Transcriptase and incubated at 42 °C for 45 min. Then, the mixture was incubated at 95 °C for 2 min and cooled down to room temperature.

**Sanger sequencing.** PCR product was precipitated by 5% sodium acetate buffer (Sigma-Aldrich) and 95% ethanol mixed solution. Then washed product was on ice for 10 min and centrifuged at 4 °C, 14,000 rpm. Supernatant was discarded and the product was rinsed this time by 70% ethanol and centrifuged 14,000 rpm. Supernatant was discarded then the products were dried using vacuum concentrator (Eppendorf). 10 μL of distilled water was added to dilute precipitated sample. When the product is all diluted in distilled water, cyclic PCR was carried out. Two separate mixtures for forward and reverse sequences were made where they each include 5X sequencing buffer (Applied Biosystems), Big Dye (Applied Biosystems), forward or reverse primer, distilled water, and product from the previous step. Cyclic PCR was carried out with denaturation step at 96 °C, annealing temperature at 55 °C, and elongation at 60 °C for 25 cycles. The cyclic PCR product was then precipitated with
5% sodium acetate buffer and 95% ethanol mixed solution and set on ice for 10 min then it was centrifuged at 4 °C and supernatants were carefully discarded and the final product was dried using the vacuum concentrator. 10 μL Hi-Di formamide (Applied Biosystems) was added to dilute the dried product. This final product was transferred to 96 well PCR plate and denatured at 95 °C for 2 min before taken to 3500xL Genetic Analyzer (Applied Biosystems) for sequencing.

**CCP analysis, targeted gene sequencing.** CCP (Comprehensive Cancer Panel) is technology using Ion Ampliseq (Thermofisher Scientific). CCP panel could detect 409 genes mutations on exomes. There are various mutation types about driver-genes. According to the manufacturer's instructions as described, gDNA was extracted from cell pellet specimen using QIAamp DNA Mini kit. Quantity and quality of obtained DNA samples was evaluated using the Qubit fluorometer and the Qubit dsDNA HS assay kit (Life Technologies, Gent, Belgium). AmpliSeq library was assembled with NEBNext® Ultra DNA Library Prep Kit for Illumina (NEB #E7370S/L) and the Ion AmpliSeq™ Library Kit 2.0 (Life Technologies, Part #4480441 Rev. 5.0). And then, the amplicons were purified by AMPure XP reagent (Beckman Coulter, Brea, CA, USA). The products were processed in end repair by NEBNext® End Prep kit (NEB #E7442). NEBNext® Multiplex Oligos for illumina (NEB #E7335 or NEB #E7500) were ligated with DNA ligase. Adapter-ligated products were then purified by AMPure XP reagent (Beckman Coulter, Brea, CA, USA), and PCR-amplified for a total of 7 cycles. The complete library was purified by AMPure XP reagent (Beckman Coulter) and GeneRead size selection kit(Qiagen). Size and concentration of the library were analyzed by Agilent 2100 BioAnalyzer and Agilent BioAnalyzer DNA High-Sensitivity LabChip (Agilent Technologies). The amplified libraries's quality was proved by capillary electrophoresis (Bioanalyzer, Agilent). Qualified libraries were mixed in index tagged in equimolar amounts of the pool, after QPCR that was taken by using SYBR Green PCR Master Mix (Applied Biosystems). Sequencing was completed using an Illumina NextSeq 500 system following referred protocols for 2 × 150 bp sequencing.

**Drug sensitivity test.** 2 × 10^5 to 4 × 10^5 viable cells from each cell line were seeded into well of 96 well plate in triplicate to measure drug sensitivity of 18 compounds. After 72 h-incubation at 37 °C, 10ul EZ-Cytox solution was added to well of each seeded lung cancer cells. After 2 h-incubation at 37 °C, optical density of EZ-Cytox-treated cells was calculated by Multiskan™ GO Microplate Spectrophotometer (Thermo Fisher Scientific). These steps were repeated in triplicate. The half maximal effective concentration (EC50) were measured by GraphPad Prism 5 (GraphPad Software). The maximum concentration and solvent are as follows.

| Drugs          | Company   | Cat no. | Solvent | Max conc. (uM) |
|----------------|-----------|---------|---------|----------------|
| Afatinib       | Selleckhem| Cat# S1011 | DMSO    | 50             |
| Alectinib      | Selleckhem| Cat# S2762 | DMSO    | 10             |
| Apitolisib     | Selleckhem| Cat# S6966 | DMSO    | 50             |
| Buparlisib (BKMI20) | Selleckhem | Cat# S2247 | DMSO    | 100            |
| Ceritinib      | Selleckhem| Cat# S7085 | DMSO    | 10             |
| Crizotinib     | Selleckhem| Cat# S5190 | DMSO    | 10             |
| Cyclopamine    | Selleckhem| Cat# S1146 | DMSO    | 50             |
| Dacomitinib    | Selleckhem| Cat# S2727 | DMSO    | 10             |
| Erlotinib Hydrochloride | Selleckhem | Cat# S1023 | DMSO    | 100            |
| Everolimus     | Selleckhem| Cat# S1120 | DMSO    | 100            |
| Gefitinib      | Selleckhem| Cat# S1025 | DMSO    | 100            |
| ICG-001        | Selleckhem| Cat# S2662 | DMSO    | 100            |
| MK-5108        | Selleckhem| Cat# S2770 | DMSO    | 100            |
| Olaparib       | Selleckhem| Cat# S1060 | DMSO    | 50             |
| Pachitaxel     | Selleckhem| Cat# S1150 | DMSO    | 50             |
| Regorafenib    | Selleckhem| Cat# S1178 | DMSO    | 100            |
| Trametinib     | Selleckhem| Cat# S2673 | DMSO    | 50             |
| Vistusertib (AZD2014) | Selleckhem | Cat# S2783 | DMSO    | 5              |

**Protein extraction and Western blotting.** Cultivated cells that had full confluency were harvested with cell scraper. Cell pellet was treated by EzRIPA buffer (ATTO Co., Tokyo, Japan) after washed by cool PBS. Whole protein was extracted by this step. Protein concentration of each cell line was determined by SMART micro BCA protein assay kit (Intron biotechnology). Proteins that fixed into equal concentration were loaded on a 4–12% Bis-Tris gel (Invitrogen) at 70 V for 3 h and then proteins on loaded gel were transferred to a PVDF membrane (Invitrogen) by electro-blotting in condition under a constant current of 80 mA at 4 °C overnight. Proteins of transferred membrane was blocked by incubating in 1.5% to 2.0% skim milk and 0.05% Tween 20-TBS buffer including 1 mM MgCl2 for an hour at room temperature. Primary antibodies were used against DKK1, β-catenin, E-cadherin, and Vimentin and β-actin. Mouse or rabbit IgG 2nd antibody (Jackson Immunoresearch, PA, USA) (1:5000) conjugated with peroxidase that matched with used 1st antibody was added to membrane. After chemiluminescent working solution, WESTZOLTM (Intron biotechnology) was treated to the membrane, the membrane was exposed to Fuji RX film (Fujiﬁlm, Tokyo, Japan) for 1–5 min. The raw and
unprocessed blotting images are provided with supplementary data file. The bloting image for DKK1 was closely cropped near the membrane edges, and we provide replicates performed as well. The MET protein level was confirmed with ChemiDoc Touch Imaging System (Bio-Rad Laboratories, CA, USA) using consecutive exposing mode with 1-min interval for 5 min.

| Target       | 2nd species | Company         | Cat no.             | Dilution |
|--------------|-------------|-----------------|---------------------|----------|
| E-Cadherin   | Rabbit      | Abcam           | Cat# 1702-1, RRID:AB_562059 | 1:1000   |
| Vimentin     | Rabbit      | Abcam           | Cat# ab63379, RRID:AB_152452 | 1:1000   |
| DKK1         | Mouse       | Abcam           | Cat# ab56905, RRID:AB_941302 | 1:1000   |
| MET          | Mouse       | Abcam           | Cat# ab51067, RRID:AB_880695 | 1:1000   |
| β-catenin    | Rabbit      | Abcam           | Cat# ab53089, RRID:AB_868701 | 1:1000   |
| β-actin      | Mouse       | Santa Cruz Biotechnology | Cat# sc-130301, RRID:AB_2223360 | 1:2000   |

**Immunocytochemistry.** Cells were seeded on chambered coverglass (Thermo Fisher Scientific, MA, USA) with a desirable cell confluence. The chambered coverglass was designed to be hydrophilic and no ECM component was treated before seeding. 72 h after cell seeding, cells were washed with cold DPBS for 15 min three times. Then, cells were fixed and permeabilized with BD Cytofix/Cytoperm™ (BD science, CA, USA). After cells were washed with washing solution (BD science), DPBS containing 2% FBS (GE Healthcare Life Sciences, Buckinghamshire, UK) was applied for an hour for blocking. After cells were washed with cold DPBS β-catenin antibody (1:500, Abcam, Cambridge, United Kingdom) diluted in 0.05% of PBS-T was applied for a 1.5 h in room temperature. Thereafter, cells were washed with 0.05% of PBS-T, and Alexa 488 and Alexa 568 secondary antibodies (Thermo Fisher Scientific, MA, USA) diluted in 0.05% of PBS-T were applied for an hour in room temperature. 1 × DAPI and Rhodamine-conjugated Phalloidin (Sigma-Aldrich, MO, USA) were diluted in distilled water and applied for 30 min in room temperature. The cells were washed with DPBS three times, and pictured under confocal microscope. LSM800 Confocal Laser Scanning Microscope and ZEN software (Carl Zeiss, Oberkochen, Germany) was used to examine cells. Diverse magnifications were used for different growth patterns and sizes of cells. The intensity of each channel was fixed for the comparison of target protein expression between samples. Digital resolution, scan speed and the number of pictures averaged were set to 1024 × 1024, 40 s per one channel, and 8 pictures respectively. The pictures were focused on the very bottom of the fixed cells for investigating protruding region of cell colonies and the location of β-catenin.

**RNA sequencing.** Total RNA was isolated from cell lysate using Trizol (Qiagen) and Qiagen RNeasy Kit (Qiagen). Sequencing libraries were prepared using the Illumina TruSeq Stranded Total RNA Library Prep Kit. Fifty-one million reads were obtained from the cell lysates. Following base-calling and alignment with the Tuxedo Suite, rejected reads were analyzed using FusionMap, ChimeraScan, and Defuse with default parameters for RNA and alignment to GRCh37.72. The output was filtered to include in-frame fusions, with at least one rescued edo Suite, rejected reads were analyzed using FusionMap, ChimeraScan, and Defuse with default parameters for RNA and alignment to GRCh37.72. The output was filtered to include in-frame fusions, with at least one rescued read and two unique seed reads, and exclude known, recurrent artifacts.

**Whole exome sequencing.** SureSelect sequencing libraries were prepared according to manufacturer’s instructions (Agilent sureselect all Exxon kit 50 Mb) using the Bravo automated liquid handler. Three micrograms of genomic DNA were fragmented to a median size of 150 bp using the Covaris-S2 instrument (Covaris, Woburn, MA). The adapter ligated DNA was amplified by PCR, and the PCR product quality was assessed by capillary electrophoresis (Bioanalyzer, Agilent). The hybridization buffer and DNA blocker mix were incubated for 5 min at 95 °C and then for10 minutes at 65 °C in a thermal cycler. The hybridization mixture was added to the bead suspension and incubated for 30 min at RT while mixing. The beads were washed, and DNA was eluted with 50 ml SureSelect elution buffer (Agilent). The flow cell loaded on HISEQ 2500 sequencing system (Illumina).

**Statistical analysis.** Statistical analysis was performed using R program version 3.3.1 (R Foundation for Statistical Computing, Vienna, Austria) with various packages including maftools, PerformanceAnalytics, survminer, survival, iplot, gplot, and lattice. Fisher’s exact test was used to analyze GO analysis of various genes. A multivariate analysis of variance (MANOVA) model was applied to the drug response data matrix with various factors such as the mutational status and the three different transcriptional subtypes. Approximate F value, p-value and Pillai’s trace score were obtained for each of the factors/drug pairs. A value of $p < 0.05$ was considered statistically significant. For hierarchical cluster analysis on a set of dissimilarities, each object was assigned to its own cluster, which an algorithm proceeds through iteratively. Two of the most similar clusters are joined at each stage until there is a single cluster. Distances between clusters are recomputed at each stage by the Lance–Williams dissimilarity update formula according to the particular clustering method being used. Clustering methods include: Ward’s minimum variance method, complete linkage method, k-means method, and single linkage method.
Received: 16 December 2021; Accepted: 4 April 2022
Published online: 15 April 2022

References
1. Takeuchi, K. et al. RET, ROS1 and ALK fusions in lung cancer. Nat. Med. 18, 378–381 (2012).
2. Jung, K. W. et al. Prediction of cancer incidence and mortality in Korea, 2017. Cancer Res. Treat. Off. J. Korean Cancer Assoc. 49, 306–312. https://doi.org/10.4143/crt.2017.130 (2017).
3. Epelbaum, O. & Rahman, N. M. Contemporary approach to the patient with malignant pleural effusion complicating lung cancer. Ann. Transl. Med. 7, 352. https://doi.org/10.21037/atm.2019.03.61 (2019).
4. Aydin, Y., Turkyilmaz, A., Intepe, Y. S. & Ergolu, A. Malignant pleural effusions: Appropriate treatment approaches. Eurasian J. Med. 41, 186–193 (2009).
5. Agalioti, T. et al. Mutant KRAS promotes malignant pleural effusion formation. Nat. Commun. 8, 15205. https://doi.org/10.1038/ncomms15205 (2017).
6. Roscilli, G. et al. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity. J. Transl. Med. 14, 61. https://doi.org/10.1186/s12967-016-0816-x (2016).
7. Paoli, P., Giannioni, E. & Chiarugi, P. Anoikis molecular pathways and its role in cancer progression. Biochem. Biophys. Acta. 1833, 3481–3498. https://doi.org/10.1016/j.bbamca.2013.06.026 (2013).
8. Dagojo-Jack, I. & Shaw, A. T. Crizotinib resistance: Implications for therapeutic strategies. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 27(Suppl 3), iii42–iii50. https://doi.org/10.1093/annonc/mdw305 (2016).
9. Ruiz, C. et al. Culture and drug profiling of patient derived malignant pleural effusions for personalized cancer medicine. PLoS ONE 11, e0160807. https://doi.org/10.1371/journal.pone.0160807 (2016).
10. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607. https://doi.org/10.1038/nature10103 (2012).
11. Never-smoker NE. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550. https://doi.org/10.1038/ nature13585 (2014).
12. Wu, S. G. et al. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur. Respir. J. 32, 924–930. https://doi.org/10.1183/09031936.00167407 (2008).
13. Bae, N. C. et al. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet. Cytoenet. 173, 107–113. https://doi.org/10.1016/j.cancergen.2006.10.007 (2007).
14. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566. https://doi.org/10.1038/nature05945 (2007).
15. Wu, S. G., Liu, Y. N., Yu, C. I., Yang, J. C. & Shih, I. Y. Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion. Genes Chromosom. Cancer 57, 513–521. https://doi.org/10.1002/gcc.22647 (2018).
16. Mroz, E. A., Tward, A. D., Hammon, R. J., Ren, Y. & Rocco, J. W. Intra-tumor genetic heterogeneity and mortality in head and neck cancer: Analysis of data from the Cancer Genome Atlas. PLoS Med. 12, e1001786. https://doi.org/10.1371/journal.pmed.1001786 (2015).
17. Katayama, R. et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 4, 120117. https://doi.org/10.1126/scitranslmed.3003316 (2012).
18. Doelebe, R. C. et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 18, 1472–1482. https://doi.org/10.1158/1078-0432.ccr-11-2966 (2012).
19. Zhang, J. et al. DKK1 promotes migration and invasion of non-small cell lung cancer via beta-catenin signaling pathway. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 39, 1010428317703820. https://doi.org/10.1177/1078043217703820 (2017).
20. Chen, C. et al. Elevated levels of Dickkopf-1 are associated with beta-catenin accumulation and poor prognosis in patients with chondrosarcoma. PLoS ONE 9, e105414. https://doi.org/10.1371/journal.pone.0105414 (2014).
21. Fr Rubiolet, L. et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 4, 662–673. https://doi.org/10.1158/2159-8290.cd-13-0846 (2014).
22. Porcel, J. M. et al. Clinical features and survival of lung cancer patients with pleural effusions. Respiratory 20, 654–659. https://doi. org/10.1111/resp.12496 (2015).
23. Porcel, J. M. Malignant pleural effusions because of lung cancer. Curr. Opin. Pulm. Med. 22, 356–361. https://doi.org/10.1097/mcp. 0000000000000264 (2016).
24. Eberhardt, W. E. et al. The IASLC Lung cancer staging project: Proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. J. Thor. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 10, 1515–1522. https://doi.org/10.1183/15560864.2015.000673 (2015).
25. Yang, S. R. et al. Comprehensive genomic profiling of malignant effusions in patients with metastatic lung adenocarcinoma. J. Mol. Diagn. IMD 20, 184–194. https://doi.org/10.1016/j.jmddx.2017.07.008 (2017).
26. Srodkon, S. et al. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations. Lung Cancer 119, 64–70. https://doi.org/10.1016/j.lungcan.2018.03.009 (2018).
27. Ruan, X. et al. Multiplexed molecular profiling of lung cancer with malignant pleural effusion using next generation sequencing in Chinese patients. Oncol. Lett. 19, 3495–3505. https://doi.org/10.3892/ol.2020.11446 (2020).
28. Chot, K., Creighton, C. J., Stivers, D., Fujimoto, N. & Kurie, J. M. Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations. PLoS ONE 2, e1226. https://doi.org/10.1371/journal.pone.0001226 (2007).
29. Takakuwa, K. et al. A novel diagnostic system to evaluate epidermal growth factor receptor impact as a prognostic and therapeutic indicator for lung adenocarcinoma. Sci. Rep. 10, 6214. https://doi.org/10.1038/s41598-020-63200-7 (2020).
30. Lin, J. J. et al. Spectrum of mechanisms of resistance to crizotinib and lorlatinib in ROS1 fusion-positive lung cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 27, 2899–2909. https://doi.org/10.1158/1078-0432.ccr-21-0032 (2021).

Acknowledgements
This study was funded in part by the Korean Cell Line Research Foundation and Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), which was funded by the Ministry of Health & Welfare (HI14C0069). Soon-Chan Kim and Ha-Young Seo received a scholarship from the BK21+ education program provided by the National Research Foundation of Korea.

Author contributions
Conceptualization, H.-Y.S., S.-C.K., Y.-K.S. and J.-L.K.; Methodology, S.-C.K., H.-Y.S., W.-L.R., S.-y.K., D.-W.K., T.M.K., and J.-L.K.; Software, S.-C.K. and H.-Y.S.; Validation, H.-Y.S.; Formal Analysis, S.-C.K., and H.-Y.S.; Investigation, H.-Y.S., S.-C.K., and W.-L.R.; Resources, Y.-K.S., S.-y.K., D.-W.K., T.M.K., and J.-L.K.; Data Curation, S.-C.K. and H.-Y.S.; Writing—Original Draft, H.-Y.S. and S.-C.K.; Writing—Review and Editing, S.-C.K.,
D.-W.K., T.M.K., and J.-L.K.; Visualization, S.-C.K. and H.-Y.S.; Supervision, D.-W.K., T.M.K., and J.-L.K.; Project Administration, J.-L.K.; Funding Acquisition, Y.-K.S. and J.-L.K.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-10318-5.

Correspondence and requests for materials should be addressed to J.-L.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022